Helix BioPharma Corp
F:HBP0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Helix BioPharma Corp
F:HBP0
|
CA |
Intrinsic Value
The intrinsic value of 
Helix BioPharma Corp (HBP0) under the Base Case is 0.08 EUR per share.
Compared with the current market price of 0.44 EUR, the stock appears
Overvalued by 81% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Helix BioPharma Does
Helix BioPharma Corp is a Canadian biotechnology company focused on developing new cancer treatments, especially immunotherapies for solid tumors. Its main work is to design and test drug candidates rather than sell approved medicines, so the company sits at the research-and-development stage of the drug pipeline.
- Headquarters
- Canada CA
- Employees
- 7
- IPO date
- Jun 3, 1996
Revenue & Expenses Breakdown
Helix BioPharma Corp
Earnings Waterfall
Helix BioPharma Corp
The intrinsic value for Helix BioPharma Corp (HBP0) under the Base Case is 0.08 EUR.
Compared with the current market price of 0.44 EUR, the stock appears Overvalued by 81% .